Multi-Omics Integration Identifies G6PD as a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Suggests Its Immunoregulatory Role
Hepatocellular carcinoma (HCC) has an insidious onset and poor prognosis, and the limited diagnostic accuracy of alpha-fetoprotein necessitates novel biomarkers. This study aims to construct an analytical framework for integrating multi-omics data from tumor tissues and single-cell transcriptomes. By integrating and analyzing the transcriptomic and clinical data of HCC, we confirmed that glucose-6-phosphate dehydrogenase (G6PD) is significantly upregulated in tumor tissues and consistently overexpressed across multiple independent cohorts, with a diagnostic area under the curve of 0.906. High G6PD expression was associated with shorter overall survival and remained an independent adverse prognostic factor. To explore the potential mechanism, a virtual knockout of G6PD was simulated on single-cell transcriptomic data, which indicated that G6PD knockout significantly perturbs immune-related pathways, including antigen processing and presentation and phagocytosis. These findings not only highlight the potential of G6PD as a candidate diagnostic and prognostic biomarker for HCC but also suggest its involvement in the tumor immune microenvironment, offering new directions for further research on the diagnosis and treatment of HCC.
Authors
- Xiaokang Jia (ORCID: https://orcid.org/0000-0001-6449-8352)
- Aimin Gong (ORCID: https://orcid.org/0000-0003-1558-1250)
- Yinhai Wang (ORCID: https://orcid.org/0000-0002-3671-4932)
- Miao Tian
- Yue Hu
- Xiping Yu
- Wenyi Zhuang
Institutions
- Zhejiang Chinese Medical University (CN)
- Hainan Medical University (CN)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3390/ijms272210393
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00